Press releases

Regulatory

December 2, 2021

Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia

Regulatory

November 18, 2021

Interim report for the period January 1, 2021 – September 30, 2021

Regulatory

October 21, 2021

Oasmia announces global settlement of all disputes with MGC Capital, former Board Members of Oasmia and members of former management

Regulatory

September 20, 2021

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

Regulatory

August 19, 2021

Interim report for the period January 1, 2021 – June 30, 2021

Regulatory

May 27, 2021

Report from Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory

May 27, 2021

Interim report for the period January 1, 2021 – March 31, 2021

Regulatory

April 29, 2021

Oasmia publishes Annual Report for 2020

Regulatory

April 27, 2021

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory

April 27, 2021

The Nomination Committee of Oasmia proposes Andrea Buscaglia as new Board member

Regulatory

March 24, 2021

Oasmia wins sole rights to record patents in its own name and is awarded full legal costs

Regulatory

March 1, 2021

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Regulatory

February 19, 2021

Year-end report^[1] for the shortened^[2] financial year May 1, 2020 – December 31, 2020